LONDON, June 17 (Reuters) - British drug developer Scancell said on Friday it was suspending dosing in a cancerclinical trial because of quality problems with itsimmunotherapy treatment SCIB1.
The company said tests showed the product, which is beingassessed for melanoma, was "no longer within the originalspecification".
Scancell is planning to make a fresh batch of SCIB1. (Reporting by Ben Hirschler; Editing by Alexander Smith)